Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal

Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company,  for around $470 million, aiming to strengthen its research pipeline with a potential new Alzheimer's treatment.

Under the agreement, Vigil shareholders will receive $8 per share, along with the possibility of an extra $2 per share through a contingent value right (CVR). This CVR depends on the progress of a drug Vigil is developing to treat Alzheimer’s.

If the CVR conditions are met, the total value of the deal could rise to approximately $600 million. The transaction is expected to be finalized in the third quarter and, according to Sanofi, it will not impact its financial guidance for 2025.

Through this acquisition, Sanofi (NASDAQ:SNY) would gain access to VG-3927, an experimental oral therapy for Alzheimer’s. The company had already invested $40 million in Vigil in June 2024, securing exclusive negotiation rights for the drug.

However, Vigil’s VGL101 monoclonal antibody program is not part of the deal and will be returned to Amgen, the U.S. pharmaceutical firm.

Earlier this month, Sanofi (NASDAQ:SNY) also disclosed plans to invest at least $20 billion in U.S.-based manufacturing and research by 2030, through both its own facilities and collaborations with domestic partners. SNY has surged by nearly 10% since the start of 2025.

While we acknowledge the potential of SNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than SNY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ MORE: 10 Biggest Dividend Cuts and Suspensions of 2024 and 10 Unstoppable Dividend Stocks to Buy Now

Disclosure. None.